Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT‐MMO trial
Lam C, Rodriguez A, Aminian A, Ferrannini E, Heerspink H, Jastreboff A, Laffin L, Pandey A, Ray K, Ridker P, Sanyal A, Yki‐Jarvinen H, Mason D, Strzelecki M, Bartee A, Cui C, Hurt K, Linetzky B, Bunck M, Nissen S. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT‐MMO trial. Obesity 2025, 33: 1645-1656. PMID: 40545827, DOI: 10.1002/oby.24332.Peer-Reviewed Original ResearchSecondary cardiovascular disease preventionCardiovascular disease preventionCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptide receptorPeptide-1 receptor agonistsMultiple cardiovascular risk factorsCardiovascular risk factorsHeart failure eventsNonfatal myocardial infarctionType 2 diabetesReduction of morbidityDisease preventionDouble-blindPrimary endpointReceptor agonistsClinical benefitImprove morbidityObesityCoronary revascularizationRisk factorsOutcome trialsTirzepatideMultiple outcomesSubstantial weight reduction
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply